| Original Research Online Publishing Date: | ||||||||||||
A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh.
| ||||||||||||
| How to Cite this Article |
| Pubmed Style Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. Natl J Physiol Pharm Pharmacol. 2015; 5(1): 28-32. doi:10.5455/njppp.2015.5.120720141 Web Style Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. https://www.njppp.com/?mno=161490 [Access: March 14, 2024]. doi:10.5455/njppp.2015.5.120720141 AMA (American Medical Association) Style Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. Natl J Physiol Pharm Pharmacol. 2015; 5(1): 28-32. doi:10.5455/njppp.2015.5.120720141 Vancouver/ICMJE Style Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. Natl J Physiol Pharm Pharmacol. (2015), [cited March 14, 2024]; 5(1): 28-32. doi:10.5455/njppp.2015.5.120720141 Harvard Style Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh (2015) A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. Natl J Physiol Pharm Pharmacol, 5 (1), 28-32. doi:10.5455/njppp.2015.5.120720141 Turabian Style Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. 2015. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. National Journal of Physiology, Pharmacy and Pharmacology, 5 (1), 28-32. doi:10.5455/njppp.2015.5.120720141 Chicago Style Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. "A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia." National Journal of Physiology, Pharmacy and Pharmacology 5 (2015), 28-32. doi:10.5455/njppp.2015.5.120720141 MLA (The Modern Language Association) Style Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. "A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia." National Journal of Physiology, Pharmacy and Pharmacology 5.1 (2015), 28-32. Print. doi:10.5455/njppp.2015.5.120720141 APA (American Psychological Association) Style Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh (2015) A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. National Journal of Physiology, Pharmacy and Pharmacology, 5 (1), 28-32. doi:10.5455/njppp.2015.5.120720141 |
